Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

Analysis of the efficacy of autologous adipose-derived stromal vascular fraction and calcium phosphate bone cement combined with core decompression in patients with femoral head necrosis: a retrospective study.

Zhang J., Zhao T., Wu Y., Li Y., Liu Z., Qian T.

Retrospective Study with a reported sample of 148 on Immune Modulation, published in BMC Musculoskelet Disord (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
BMC Musculoskelet Disord (2026)
Country
England
Reported sample size
148
Source database
PubMed
PMID
41782103
PMCID
PMC13069780
DOI
10.1186/s12891-026-09619-x

Abstract (original English)

BACKGROUND: Osteonecrosis of the femoral head (ONFH) is a progressive disorder characterized by impaired perfusion, inflammation, neural dysregulation, and structural failure of the femoral head. While core decompression (CD) is commonly used for joint preservation, its effectiveness remains limited, particularly in the absence of adequate structural support and biological modulation. Adipose-derived stromal vascular fraction (SVF) has emerged as a potential biological adjunct due to its angiogenic, immunomodulatory, and regenerative properties. This study aimed to evaluate the clinical outcomes of combining autologous SVF and calcium phosphate cement (CPC) with CD in patients with ONFH. METHODS: We retrospectively analyzed 148 patients (219 hips) with ONFH treated between 2009 and 2022. Eighty-five hips underwent CD alone (CD group), and 134 hips received SVF combined with CPC and CD (SVF + CPC + CD group). Radiographic progression and conversion to total hip arthroplasty (THA) were assessed according to the Association Research Circulation Osseous (ARCO) staging system. Hip survival was evaluated using Kaplan–Meier analysis, and multivariable Cox proportional hazards regression was performed to identify factors associated with conversion to THA. Clinical outcomes were assessed using the Harris Hip Score (HHS), visual analogue scale (VAS), and the 36-Item Short Form Health Sur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansFemaleRetrospective StudiesMaleFemur Head NecrosisCalcium PhosphatesDecompression, SurgicalAdultMiddle AgedTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research